EGFR and non-small cell lung carcinoma: Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR-tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, and afatinib, was effective in patients with NSCLC with EGFR-activating mutations.